Free Trial
→ The warning signs most investors see too late (From Weiss Ratings) (Ad)tc pixel
NASDAQ:ASND

Ascendis Pharma A/S Q3 2026 Earnings Date & Estimates

Ascendis Pharma A/S logo
$256.82 +3.37 (+1.33%)
Closing price 11/6/2026 04:00 PM Eastern
Extended Trading
$257.75 +0.93 (+0.36%)
As of 11/6/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. The conference call is scheduled for 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Ascendis Pharma A/S in Q3 2026

Ascendis Pharma A/S is expected to post earnings of $0.8940 per share on revenue of $409.40 million. In the same quarter a year earlier Ascendis Pharma A/S reported -$1.17 per share on revenue of $250.71 million. Ascendis Pharma A/S last reported on August 14, 2026, posting $1.0270 per share and missing the $1.71 consensus estimate. Ascendis Pharma A/S has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.8940
Expected Revenue
$409.40 million
Prior-Year EPS
-$1.17
Prior-Year Revenue
$250.71 million
Expected Revenue Growth
+63.3%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$1.0270 (Missed by -$0.6830)
Last Quarter Revenue
$387.22 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

Ascendis Pharma A/S Q3 2026 Earnings FAQ

Ascendis Pharma A/S (NASDAQ:ASND) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Ascendis Pharma A/S' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Ascendis Pharma A/S to post earnings of $0.8940 per share for Q3 2026.

The consensus revenue estimate for Ascendis Pharma A/S is $409.40 million for Q3 2026.

Ascendis Pharma A/S Earnings Headlines

Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union
November 6 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/06/3397481/0/en/once-weekly-transcon-cnp-navepegritide-to-receive-10-years-of-market-exclusivity-upon-approval-in-the-european-union.html
Ascendis Pharma A/S (NASDAQ:ASND) Stock Gets Downgrade from Wall Street Zen
November 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31172838
Bezos… DOOMED?
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing December 8th.tc pixel
 |  Paradigm Press (Ad)
Ascendis Pharma A/S (NASDAQ:ASND) Upgraded at Canaccord Genuity Group
October 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31164583
Morgan Stanley Sticks to Their Buy Rating for Ascendis Pharma (ASND)
October 28, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ASND/pressreleases/8476714/morgan-stanley-sticks-to-their-buy-rating-for-ascendis-pharma-asnd/
Ascendis Pharma A/S announces TransCon PTH pooled data showing kidney function improvements for up to 5 years
October 26, 2026  |  msn.comhttps://www.msn.com/en-us/health/general/ascendis-pharma-a-s-announces-transcon-pth-pooled-data-showing-kidney-function-improvements-for-up-to-5-years/ar-AA2g73a3
See More Ascendis Pharma A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ascendis Pharma A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ascendis Pharma A/S and other key companies, straight to your email.

About Ascendis Pharma A/S

Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines.

Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism. Both products have received regulatory approval in the United States and Europe.

Ascendis also develops investigational therapies for rare diseases, including TransCon CNP for achondroplasia. The company is led by co-founder and Chief Executive Officer Jan Mikkelsen and serves patients through commercial and development activities in the United States, Europe and other markets.

View Ascendis Pharma A/S Profile
Earnings Tools